• Independent observational use of SPONTAN reported positive outcomes in younger men with performance-related erectile difficulties
• All participants reported achieving and maintaining erections sufficient for intercourse following SPONTAN use
• Younger men with performance-related erectile difficulties represent an underserved segment of the global ED market

LTR Pharma Limited (ASX:LTP) has announced that a small, independent observational case series has reported positive real-world use of its intranasal erectile dysfunction product, SPONTAN, in men experiencing situational erectile difficulties associated with sexual performance anxiety. The observations involved five physically healthy men aged 20-30 years who self-identified as experiencing sexual performance anxiety. All participants reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activity, which they attributed to performance anxiety. SPONTAN nasal spray was used 10-20 minutes prior to partnered sexual activity, and all five participants reported achieving and maintaining an erection sufficient for intercourse when using SPONTAN. Reported adverse effects were limited to mild-to-moderate, transient nasal discomfort and sneezing, which resolved spontaneously within approximately five minutes. Three participants noted that nasal symptoms diminished with repeated use over a two-week period. The observations were based on self-reported outcomes and were not conducted as part of a registered or controlled clinical trial. Limitations include the small sample size, absence of a control group, short follow-up period, and reliance on subjective reporting. However, the Company believes this population represents a meaningful and underserved segment of the global erectile dysfunction market, where rapid onset and situational use may be particularly relevant. LTR Pharma intends to evaluate the potential for a clinician-initiated clinical study in men experiencing sexual performance anxiety or situational erectile difficulties in the coming year.

LTR Pharma intends to evaluate the potential for a clinician-initiated clinical study in men experiencing sexual performance anxiety or situational erectile difficulties in the coming year.